Compare APOG & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APOG | BWAY |
|---|---|---|
| Founded | 1949 | 2003 |
| Country | United States | Israel |
| Employees | N/A | 129 |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.1M | 674.2M |
| IPO Year | 1994 | N/A |
| Metric | APOG | BWAY |
|---|---|---|
| Price | $37.64 | $14.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $47.00 | $13.25 |
| AVG Volume (30 Days) | ★ 149.7K | 149.3K |
| Earning Date | 04-24-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.52 | N/A |
| Revenue | ★ $1,404,733,000.00 | N/A |
| Revenue This Year | N/A | $309.69 |
| Revenue Next Year | $2.07 | $26.21 |
| P/E Ratio | ★ $15.31 | $81.98 |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $30.75 | $10.21 |
| 52 Week High | $46.14 | $26.63 |
| Indicator | APOG | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 56.29 | 35.47 |
| Support Level | $36.94 | $11.90 |
| Resistance Level | $37.97 | $16.51 |
| Average True Range (ATR) | 1.17 | 0.55 |
| MACD | 0.30 | -0.16 |
| Stochastic Oscillator | 71.53 | 9.03 |
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company geographically operates in the United States, Canada, and Brazil, with the majority revenue generated from the United States.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.